Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies (Zotatifin)
A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Intravenous Zotatifin (eFT226) in Subjects With Selected Advanced Solid Tumor Malignancies
Sponsor: Effector Therapeutics
A PHASE1/PHASE2 clinical study on Solid Tumor, Adult, this trial is actively recruiting participants. The trial is conducted by Effector Therapeutics and has accumulated 17 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
17 versions recorded-
Sep 2024 — Present [monthly]
Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2024 — Jun 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Oct 2023 — Jan 2024 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 12 earlier versions
-
Aug 2023 — Oct 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Dec 2022 — Aug 2023 [monthly]
Recruiting PHASE1_PHASE2
-
May 2022 — Dec 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Apr 2022 — May 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2022 — Apr 2022 [monthly]
Recruiting PHASE1_PHASE2
-
May 2021 — Feb 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2021 — May 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Aug 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
-
May 2020 — Aug 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Apr 2020 — May 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2020 — Apr 2020 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Oct 2019 — Jan 2020 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Effector Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .